Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

254 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients, and the changes in the microbiological characteristics reported in the last years are impacting the choice of antibiotic used in the treatment. Cefotaxime has been the most extensively studied antibiotic for this infection. It is considered to be one of the first choice antibiotics because of low toxicity and excellent efficacy. Treatment of SBP by intravenous cefotaxime should be administered for a minimum 5 days. Antibiotic-resistant microorganisms have been increasingly reported especially to cefotaxime and its effect on the clinical outcome in treating SBP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?

NCT02443285

Primary Bacterial Peritonitis

UNKNOWN PHASE3

Meropenem vs Cefotaxime as Empirical Treatment of SBP

NCT05427747

Spontaneous Bacterial Peritonitis

UNKNOWN PHASE4

Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC

NCT01265173

SBP Liver Cirrhosis

COMPLETED PHASE4

Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

NCT04168099

Spontaneous Bacterial Peritonitis

RECRUITING PHASE3

Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin

NCT06234046

Spontaneous Bacterial Peritonitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spontaneous Bacterial Peritonitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SBP-group 1

Spontanous bacterial peritonitis

Group Type EXPERIMENTAL

Cefotaxime

Intervention Type DRUG

CNNA-group 2

Culture negative neutrocytic ascites

Group Type EXPERIMENTAL

Cefotaxime

Intervention Type DRUG

MNBA-group 3

monomicrobial non-neutrocytic ascites

Group Type EXPERIMENTAL

Cefotaxime

Intervention Type DRUG

group 4

no evidence of ascitic fluid infection

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cefotaxime

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with liver cirrhosis and ascites and clinical findings suspicious of ascitic fluid infection

Exclusion Criteria

* Patients were excluded if they received antibiotics ten days prior to the hospital admission or there is evidence of secondary bacterial peritonitis, tuberculous peritonitis, malignant ascites or ascites due to other causes e.g. cardiac or renal diseases

Eligible Sex

ALL

Accepts Healthy Volunteers

No